Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis-Reference-Cited by-同舟云学术

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis

Published:2021-11-04 Issue:2 Volume:65 Page:1206-1224
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hopkins Brian T.¹^ORCID,Bame Eris¹,Bajrami Bekim¹,Black Cheryl¹,Bohnert Tonika¹,Boiselle Carrie¹,Burdette Doug¹,Burns Jeremy C.¹,Delva Luisette¹,Donaldson Douglas¹,Grater Richard¹,Gu Chungang¹,Hoemberger Marc¹,Johnson Josh¹,Kapadnis Sudarshan¹,King Kris¹,Lulla Mukesh¹,Ma Bin¹^ORCID,Marx Isaac¹,Magee Tom¹,Meissner Robert¹,Metrick Claire M.¹,Mingueneau Michael¹,Murugan Paramasivam¹,Otipoby Kevin L.¹,Polack Evelyne¹,Poreci Urjana¹,Prince Robin¹,Roach Allie M.¹,Rowbottom Chris¹,Santoro Joseph C.¹,Schroeder Patricia¹,Tang Hao¹,Tien Eric¹,Zhang Fengmei¹,Lyssikatos Joseph¹

Affiliation:

1. Research & Development, Biogen, Cambridge, Massachusetts 02142, United States

Funder

Biogen

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00926

Reference46 articles.

1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis